Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 41

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 41
---
 voting rights, dividends or other rights as a holder of our capital stock until they exercise the warrants.

Series J Warrants and July 2024 Placement Agent Warrants

The following is a brief summary of the Series J Warrants and July 2024 Placement Agent Warrants issued in connection with a July 2024 private placement, and is subject in all respects to the provisions contained in the applicable warrants,which are filed as exhibits
to our Report on Form 6-K dated July 19, 2024. Unless otherwise stated, references to “warrants” in this subsection include the Series J Warrants and July 2024 Placement Agent Warrants.

Exercisability.
The warrants became exercisable on July 22, 2024. The Series J Warrants and July 2024 Placement Agent Warrants expire five years and three years, respectively from the initial exercise date. The holder shall deliver the
aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise
(subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. If, following the date that is six months from the initial issuance date of the warrant, a registration statement
registering the issuance of the securities underlying the warrants under the Securities Act is not then effective, or the prospectus
contained therein is not available for the resale of the securities issuable upon exercise of the applicable warrants, then in lieu of
making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder
may elect instead to receive upon such exercise (either in whole or in part) the net number of Depositary Shares determined according
to a formula set forth in the warrants.

Exercise Price.The exercise price of each Series J Warrant and July 2024 Placement Agent Warrant is $250.00 per Depositary Share and $312.50 per Depositary Share, respectively.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion of a warrant, to the extent that, after giving effect
to such exercise, such holder, together with such holder’s affiliates, and any persons acting as a group together with such holder
or any such affiliate, would beneficially own in excess of 9.99% or 4.99%, at the holders determination, of the number of Ordinary Shares
outstanding immediately after giving effect to the issuance of the Ordinary Shares underlying the Depositary Shares upon such exercise.
The holder